CMS Finalizes Permanent Medicare Drug Negotiation Framework
CMS finalized a permanent framework for Medicare drug price negotiations, including selection of up to 20 additional Part D and/or Part B drugs by February 1, 2027, for prices effective in 2029. The rule creates compliance and planning implications for manufacturers, Medicare plans, and firms supporting drug pricing, formularies, benefits administration, and payment operations; it does not announce a procurement opportunity.
Key Signals
- CMS to select up to 20 additional Part B and/or Part D drugs by February 1, 2027
- Negotiated Medicare drug prices scheduled to take effect in 2029
- Part D plans must include selected drugs with an MFP in effect on formularies
- Small-biotech price floor applies to certain eligible drugs in 2029 and 2030
- Benefits, formulary, pricing, and payment vendors should assess client operational impacts
"This rule provides additional tools to help CMS negotiate better deals, achieve greater savings for taxpayers and beneficiaries, and improve health outcomes for seniors who rely on the Medicare Prescription Drug Program."
The Centers for Medicare & Medicaid Services (CMS) has issued a final rule establishing a permanent framework for the Medicare Drug Price Negotiation Program. The policies set a more predictable process for participating manufacturers as the agency continues negotiations for high-cost drugs, with the next set of negotiated prices scheduled to take effect in 2029. CMS said the framework is intended to support continued innovation while helping the agency secure savings for taxpayers and beneficiaries. CMS Administrator Dr. Mehmet Oz said, “This rule provides additional tools to help CMS negotiate better deals, achieve greater savings for taxpayers and beneficiaries, and improve health outcomes for seniors who rely on the Medicare Prescription Drug Program.”
A key implementation milestone is February 1, 2027, when CMS plans to select up to 20 additional negotiation-eligible drugs covered under Medicare Part D and/or payable under Medicare Part B. For the fourth negotiation cycle, the agency may also select drugs for renegotiation, as appropriate. This schedule gives drug manufacturers, health plans, and their service providers a defined planning horizon to assess potential exposure, prepare for program requirements, and coordinate operational changes before prices become applicable in 2029. The announcement does not identify a solicitation, contract award, or contract value.
The final rule also addresses program integrity and price-setting protections. It finalizes a policy for certain fixed-combination drugs that CMS determines are new formulations of existing drugs. CMS said the policy is intended to avoid incentives for a primary manufacturer to shift patients to a new formulation to circumvent application of the maximum fair price (MFP). In addition, as required by law, the rule implements a Temporary Floor for Small Biotech Drugs. For certain eligible small-biotech drugs in initial price applicability years 2029 and 2030, CMS may not offer or accept a counteroffer for an MFP below the specified floor.
For GovCon organizations, the most direct implications are regulatory and operational rather than an immediate buying opportunity. Firms supporting manufacturers and Part D plans in pricing analytics, formulary management, benefit administration, claims, and payment processing should review how the finalized requirements affect their clients’ systems and workflows. The rule codifies requirements for Part D plans to include selected drugs with an MFP in effect on their formularies, and it limits negotiated prices paid by plans to dispensing entities to the MFP plus any dispensing fees. Contractors should treat the 2027 selection date and 2029 effective pricing as planning milestones, while monitoring CMS guidance and the final rule’s implementation details.
- CMS finalized a permanent framework for the Medicare Drug Price Negotiation Program, intended to provide greater predictability for participating manufacturers.
- By February 1, 2027, CMS plans to select up to 20 additional drugs eligible for negotiation under Part D and/or payable under Part B.
- CMS may select drugs for renegotiation, as appropriate, as part of the fourth negotiation cycle.
- Negotiated prices under the framework are scheduled to take effect beginning in 2029.
- For certain fixed-combination drugs CMS considers new formulations of existing drugs, the rule aims to prevent circumvention of the maximum fair price through patient shifts to a new formulation.
- The Temporary Floor for Small Biotech Drugs bars CMS from offering or accepting a counteroffer below a specified price floor for certain eligible drugs in 2029 and 2030.
- Part D plans must include selected drugs with an MFP in effect on their formularies.
- Part D negotiated prices paid to dispensing entities are limited to the MFP plus applicable dispensing fees.
- Service providers should assess impacts on pricing, formulary, benefits-administration, and payment operations, and use the 2027 and 2029 dates for implementation planning.
- The announcement is a regulatory development, not a procurement notice: it names no solicitation, award, or contract value.
Agencies
- Centers for Medicare & Medicaid Services (CMS)